Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Brokerages

Immunic, Inc. (NASDAQ:IMUX) has been assigned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $7.40.

IMUX has been the subject of a number of recent research reports. HC Wainwright dropped their target price on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. Roth Capital initiated coverage on shares of Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $8.00 target price on shares of Immunic in a research report on Wednesday, January 7th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Qube Research & Technologies Ltd bought a new stake in shares of Immunic in the 3rd quarter valued at about $29,000. Focus Partners Wealth increased its stake in Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after purchasing an additional 39,063 shares during the period. Two Sigma Investments LP bought a new stake in Immunic in the third quarter valued at approximately $52,000. HB Wealth Management LLC bought a new stake in Immunic in the third quarter valued at approximately $81,000. Finally, Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter valued at approximately $99,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Up 2.4%

IMUX opened at $0.68 on Wednesday. The business’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.79. Immunic has a 52 week low of $0.51 and a 52 week high of $1.39. The stock has a market cap of $81.47 million, a PE ratio of -0.82 and a beta of 1.54.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. As a group, equities analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.